BRCA2 and invasive breast carcinoma: The sensitivity and specificity of evaluating serum anti-BRCA2 AAbs were 34% and 92%, respectively, for invasive breast carcinoma, and 23% and 92%, respectively, for ductal carcinoma in situ.